tadalafil + tamsulosin (Yungjin Pharmaceutical)

**Tadalafil + tamsulosin** is an oral fixed-dose combination of two small molecules developed as HCP1303 and marketed by Hanmi Pharmaceutical as Gugutams, with Aditams used as the Mexican brand. It combines tadalafil, a selective phosphodiesterase type 5 inhibitor that enhances nitric oxide-cyclic guanosine monophosphate signaling, with tamsulosin, a selective alpha-1 adrenergic receptor antagonist that reduces smooth-muscle tone in the prostate and bladder neck. The combination is intended for men with lower urinary tract symptoms associated with benign prostatic hyperplasia and concomitant erectile dysfunction. Hanmi-sponsored Phase 3 and pharmacokinetic studies evaluated the HCP1303 capsule, and Hanmi reports that the product is marketed for benign prostatic hyperplasia-related obstructive prostatic symptoms and erectile dysfunction. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02667938?tab=table))

Brand names

AditamsGugutams

Other names

tadalafil/tamsulosintamsulosin + tadalafiltamsulosin/tadalafil